Macrogen, Inc.

Equities

A038290

KR7038290003

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
20,050 ^KRW	+0.80%		+3.62%	-4.52%

2023	Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	CI
2023	Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	CI

Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.

November 31, 2021

From November 2, 2020 to December 31, 2020, the company has repurchased 80,000 shares, representing 0.81% for KRW 2,157.48 million. With this, the company has completed the repurchase of 80,000 shares, representing 0.81% for KRW 2,157.48 million under the buyback announced on November 2, 2020.

Latest news about Macrogen, Inc.

Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-10-24	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-10-24	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-10-24	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-10-24	CI
Macrogen, Inc.'s Equity Buyback announced on October 21, 2022, has expired with 138,097 shares, representing 1.37% for KRW 2,825.59 million.	23-10-19	CI
Macrogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-01-25	CI
Macrogen, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	22-10-21	CI
Macrogen, Inc. authorizes a Buyback Plan.	22-10-20	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.	21-10-31	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.	21-10-31	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.	21-10-31	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.	21-10-31	CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.	21-10-31	CI
Macrogen, Inc.'s Equity Buyback announced on November 2, 2020, has expired with 168,300 shares, representing 1.72% for KRW 4,957.38 million.	21-10-31	CI
Macrogen, Inc.(KOSDAQ:A038290) added to S&P Global BMI Index	21-09-20	CI
Macrogen, Inc.(KOSDAQ:A038290) dropped from S&P Global BMI Index	21-03-22	CI
Macrogen, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.	20-11-01	CI
Macrogen, Inc. authorizes a Buyback Plan.	20-11-01	CI
Macrogen Signs Export Agreement with LG International	20-09-23	CI
Macrogen, Inc. Obtains Export Approval for COVID-19 Test Kit AxenTM Covid-19 RT	20-05-20	CI
Macrogen Approves for Export of Its COVID-19 Test Kit	20-05-20	CI
Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific	20-01-13	CI
Macrogen, Inc.’s Equity Buyback announced on January 11, 2019, has expired.	20-01-09	CI
Seoul National University Bundang Hospital and Macrogen Announce Construction of Northeast Asian Reference Panel	19-12-02	CI

Chart Macrogen, Inc.

Duration

Period

More charts

Company Profile

Macrogen, Inc. is a Korea-based company mainly engaged in the customized transgenic and other services in the field of biomedical research. The Company operates its business through four divisions: deoxyribonucleic acid (DNA) sequencing division, DNA chips division, transgenic and knockout mouse division and oligonucleotide DNA division. Its DNA sequencing division provides genome sequencing analysis services. Its DNA chips division develops DNA chips products, such as Illumina chips, MacArray chips and customized chips. Its transgenic and knockout mouse division offers gene engineering services. Its oligonucleotide DNA division offers oligonucleotide DNA manufacturing services. The Company operates its business within domestic market and in overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Macrogen, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20,050 KRW

Average target price

30,000 KRW

Spread / Average Target

+49.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MACROGEN, INC.	-4.52%	145M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research